PR

MEZOO, connecting health through technology
Sharing MEZOO’s technology and vision.
External
2026.07.30
MEZOO Reports 104% Increase in Q2 Revenue on Expanded SmartPatch Supply

 

Q2 Revenue Reaches KRW 5.7 Billion, Operating Profit KRW 900 Million
“Securing New Revenue Streams with Next-Generation Product Launches”
 

MEZOO more than doubled its second-quarter revenue, driven by expanded supply of its wireless smart patches capable of monitoring multiple vital signs.


The company announced on July 29 that it recorded KRW 5.7 billion in revenue and KRW 900 million in operating profit for the second quarter of 2026.

Revenue increased 104% year over year, while operating profit rose 73%.

Net profit also climbed 334% year over year to KRW 1.1 billion.
 

The strong performance was primarily driven by expanded deployment of its flagship wireless smart patch, HiCardi+.

In particular, strengthened sales activities by its strategic partner, Dong-A ST, contributed to broader adoption across healthcare institutions.

MEZOO’s HiCardi+ is a wearable solution that continuously monitors patients’ vital signs even while they are moving throughout the hospital.



Source : https://news.nate.com/view/20260729n26919

 

적용 법률 및 규정
의료기기

하이카디® 시스템은 인허가에 따라 신생아, 소아, 청소년, 18세 이상 환자의 ECG 데이터를 측정하여 부정맥을 진단하는 의료기기로서 의료전문가가 사용하도록 설계되었습니다. 한국 KFDA로부터 의료기기 2등급 인증을 받았습니다. 유럽의료기기 지침(2007/47/EC에 따라 개정된 MDD 93/42/EEC)에 따라 준수된 Class IIb (CE2265). 의료기기 제품으로 CE 승인되었습니다. 미국 FDA는 Class II 510K로 승인 완료 예정입니다.

경고

본 자료는 의료 전문가에게만 배포되며 관련 사진과 함께 제공되는 자료와 관련하여 그 어떤 법적인 책임을 갖지 않습니다. 사용 전 사용 지침서를 주의 깊게 읽으십시오.